The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "cytokine storm"

Search results for: cytokine storm

Investigation Continues on Repurposed Rheumatology Therapies for COVID-19 Cytokine Storm

November 14, 2020 • By Ruth Jessen Hickman, MD

Roberto Caricchio, MD, discusses what trials of repurposed rheumatology drugs to treat COVID-19 cytokine storm have shown so far.... [Read More]

Filed Under: ACR Convergence, Meeting Reports Tagged With: ACR Convergence 2020, COVID-19

Don’t Forget the Host: COVID-19 Cytokine Storm

March 16, 2020 • By Randy Q. Cron, MD, PhD, & W. Winn Chatham, MD

The new coronavirus outbreak, COVID-19, reminds us how we have struggled to keep ahead of mutating pathogens through the ages.... [Read More]

Filed Under: Conditions Tagged With: COVID-19

Driving through the Storm: A Pediatric Rheumatologist Finds a Pandemic of Rheumatic Disease

May 18, 2020 • By Mark Gorelik, MD

A pediatric rheumatologist in the thick of treating children with COVID-19 confronts a new and evolving syndrome.... [Read More]

Filed Under: Conditions, Opinion Tagged With: COVID-19, Pediatrics

ACR Convergence 2020 Kicks Off: Plenary session speakers highlight racial differences in lupus & COVID-19-related findings

November 7, 2020 • By Ruth Jessen Hickman, MD

ACR CONVERGENCE 2020—The ACR’s first fully virtual annual meeting kicked off on Thursday, Nov. 5. During the Opening Session, ACR President Ellen M. Gravallese, MD, talked about how the specialty’s response during the pandemic has provided great hope and will help rheumatology become an even more essential specialty. At the first Plenary Session on Friday,… [Read More]

Filed Under: ACR Convergence, Conditions, Meeting Reports, SLE (Lupus), Systemic Inflammatory Syndromes Tagged With: ACR Convergence 2020, ACR Convergence 2020 - SLE, COVID-19, Global Rheumatology Alliance

Oxford University to Study Adalimumab as Potential COVID-19 Treatment

September 30, 2020 • By Josephine Mason & Kate Kelland

LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown… [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: adalimumab, COVID-19

Jury Out on Immunomodulatory Therapy for Kids with Severe COVID-19

September 1, 2020 • By Megan Brooks

NEW YORK (Reuters Health)—Immunomodulatory therapy is not recommended for most children with COVID-19 who typically will have a mild to moderate course of illness, experts advise in a guidance document in the Journal of the Pediatric Infectious Diseases Society.1 For children with severe or critical COVID-19, immunomodulatory agents “may be beneficial,” but the risks and… [Read More]

Filed Under: Conditions Tagged With: Children, COVID-19, Pediatric

Respiratory Failure More Common in COVID-19 Patients with Rheumatic Disease

June 23, 2020 • By Marilynn Larkin

NEW YORK (Reuters Health)—COVID-19-infected patients with rheumatic disease were more likely to experience respiratory failure than those without rheumatic disease, according to a retrospective study in China. “Immune dysregulation underlying rheumatic diseases may affect the disease manifestation of COVID-19,” Dr. Jixin Zhong of Huazhong University of Science and Technology, Wuhan, tells Reuters Health by email…. [Read More]

Filed Under: Uncategorized Tagged With: coronavirus, COVID-19, respiratory, Rheumatic Disease

Rheumatology Biologic Expertise Valued for COVID-19 Treatment Decisions

May 18, 2020 • By Catherine Kolonko

At the Loma Linda University Medical Center, Calif., rheumatologists play a key consulting role for COVID-19 patients who may benefit from the use of biologic treatments…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biologics, coronavirus, COVID-19, cytokine storm syndrome, Cytokines, macrophage activation syndrome

The COVID-19 Infection Inflammation Equation

May 14, 2020 • By Candice Reyes, MD, RhMSUS

The uncertainty is certain Let us draw up the curtain Unmask this serial killer’s intention. Attack of its clones gone viral Made distancing societal Disrupting every human convention. Humble hydroxychloroquine Now forced into the scene Telehealth bridges our care. Drive-thru testing PPE and sanitizing Social media fills the air. But let’s not be deceived This… [Read More]

Filed Under: Conditions, Professional Topics Tagged With: COVID-19

Arthritis Drug Anakinra Shows Promise in COVID-19

May 12, 2020 • By Megan Brooks

NEW YORK (Reuters Health)—Treatment with the interleukin-1 blocker anakinra appears to improve respiratory symptoms and reduced signs of cytokine storm in nearly three-quarters of patients with acute respiratory distress and cytokine release syndrome from COVID-19 in a small retrospective study from Italy. “Our study is the first to suggest that a high dose of the… [Read More]

Filed Under: Drug Updates Tagged With: anakinra, coronavirus, COVID-19

  • 1
  • 2
  • 3
  • Next Page »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.